Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
Holding EW?
Track your performance easily
EW Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$58.93 - $96.12
Previous Close$67.53
Volume9.59M
Average Volume (3M)6.15M
Market Cap
$40.68B
Enterprise Value$39.45B
Total Cash (Recent Filing)$1.99B
Total Debt (Recent Filing)$693.00M
Price to Earnings (P/E)27.8
Beta1.26
Next Earnings
Oct 23, 2024EPS Estimate
$0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.43
Shares Outstanding602,400,000
10 Day Avg. Volume7,511,075
30 Day Avg. Volume6,149,044
Standard Deviation0.10
R-Squared0.37
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)5.44
Price to Sales (P/S)6.96
Price to Cash Flow (P/CF)27.80
P/FCF Ratio34.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.58
Enterprise Value/Gross Profit8.53
Enterprise Value/Ebitda23.53
Forecast
1Y Price Target
$78.17Price Target Upside15.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
Edwards Lifesciences News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsExpectations for the EARLY-TAVR trial in asymptomatic aortic stenosis to be positive and drive modest acceleration in TAVR market growth.
Share BuybackA $1 billion share buyback program has been announced.
ValuationThe stock is viewed as attractively valued at current levels.
Bears Say
Financial PerformanceManagement confirmed that 2025 EPS will be 'markedly lower' than EW's most recent 2024 EPS guidance.
Growth And Market CompetitionThe near-term outlook is clouded by TAVR growth decelerating and price competition in Europe, reducing the likelihood of a quick rebound.
Operational ChallengesDocs cited challenges with staffing, lab capacity, anesthesiology access, and growing multiple treatment lines at once, echoing EW's 2Q call-out.
---
Ownership Overview
1.09% Insiders
24.37% Mutual Funds
38.36% Other Institutional Investors
36.18% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $58.93 and its highest was $96.12 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Currently, no data Available
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Oct 23, 2024 which is in 34 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Jul 24, 2024. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of $0.694 by $0.006.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is $0.67.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 602,400,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.7 in its last earnings report, beating expectations of $0.694. Following the earnings report the stock price went down -31.34%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Among the largest hedge funds holding Edwards Lifesciences’s share is Fisher Asset Management LLC. It holds Edwards Lifesciences’s shares valued at 764M.
---
Edwards Lifesciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$78.17 (15.76% Upside)
$78.17 (15.76% Upside)
Blogger Sentiment
Bullish
EW Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 971.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $87.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.41%
12-Months-Change
Fundamentals
Return on Equity
21.35%
Trailing 12-Months
Asset Growth
12.16%
Trailing 12-Months
Company Description
Edwards Lifesciences
Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.
---
EW Earnings Call
Q2 2024
0:00 / 0:00
---
EW Net sales Breakdown
64.61% Transcatheter Aortic Valve Replacement
16.64% Surgical Structural Heart
15.46% Critical Care
3.29% Transcatheter Mitral and Tricuspid Therapies
---
EW Stock 12 Month Forecast
Average Price Target
$78.17
▲(15.76% Upside)
Technical Analysis
Best Analysts Covering EW
1 Year
1 Year Success Rate
22/34 ratings generated profit
1 Year Average Return
+13.21%
reiterated a buy rating 8 days ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +13.21% per trade.
---